Prediction of drugs having opposite effects on disease genes in a directed network

BackgroundDeveloping novel uses of approved drugs, called drug repositioning, can reduce costs and times in traditional drug development. Network-based approaches have presented promising results in this field. However, even though various types of interactions such as activation or inhibition exist in drug-target interactions and molecular pathways, most of previous network-based studies disregarded this information.MethodsWe developed a novel computational method, Prediction of Drugs having Opposite effects on Disease genes (PDOD), for identifying drugs having opposite effects on altered states of disease genes. PDOD utilized drug-drug target interactions with ‘effect type’, an integrated directed molecular network with ‘effect type’ and ‘effect direction’, and disease genes with regulated states in disease patients. With this information, we proposed a scoring function to discover drugs likely to restore altered states of disease genes using the path from a drug to a disease through the drug-drug target interactions, shortest paths from drug targets to disease genes in molecular pathways, and disease gene-disease associations.ResultsWe collected drug-drug target interactions, molecular pathways, and disease genes with their regulated states in the diseases. PDOD is applied to 898 drugs with known drug-drug target interactions and nine diseases. We compared performance of PDOD for predicting known therapeutic drug-disease associations with the previous methods. PDOD outperformed other previous approaches which do not exploit directional information in molecular network. In addition, we provide a simple web service that researchers can submit genes of interest with their altered states and will obtain drugs seeming to have opposite effects on altered states of input genes at http://gto.kaist.ac.kr/pdod/index.php/main.ConclusionsOur results showed that ‘effect type’ and ‘effect direction’ information in the network based approaches can be utilized to identify drugs having opposite effects on diseases. Our study can offer a novel insight into the field of network-based drug repositioning.

[1]  T. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2010, Nucleic Acids Res..

[2]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[3]  Jun Zou,et al.  Neighbor communities in drug combination networks characterize synergistic effect. , 2012, Molecular bioSystems.

[4]  T. Hogan,et al.  Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib , 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[5]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[6]  J. Davis Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[7]  Bin Chen,et al.  Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..

[8]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[9]  Antoine H. C. van Kampen,et al.  Consensus and conflict cards for metabolic pathway databases , 2013, BMC Systems Biology.

[10]  Yuhao Wang,et al.  Predicting drug-target interactions using restricted Boltzmann machines , 2013, Bioinform..

[11]  Bo Zhang,et al.  Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.

[12]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[13]  Fiorenza Gianì,et al.  Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. , 2013, The Journal of clinical endocrinology and metabolism.

[14]  Michiaki Mishima,et al.  Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Stimson P. Schantz,et al.  Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer , 2011, PloS one.

[16]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[17]  Carlos Matute,et al.  Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.

[18]  Sungji Choo,et al.  Context-based resolution of semantic conflicts in biological pathways , 2015, BMC Medical Informatics and Decision Making.

[19]  H. Lowe,et al.  Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches. , 1994, JAMA.

[20]  Yutaka Yamamoto,et al.  Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells , 2006, Cancer Chemotherapy and Pharmacology.

[21]  Mohammed Al-Shalalfa,et al.  Prediction of novel drug indications using network driven biological data prioritization and integration , 2014, Journal of Cheminformatics.

[22]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[23]  Thomas C. Wiegers,et al.  Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical–gene–disease networks , 2008, Nucleic Acids Res..

[24]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[25]  M. Landriscina,et al.  Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. , 2010, Anticancer research.

[26]  Thomas J Lynch,et al.  A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[27]  Stefan Wiemann,et al.  KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor , 2009, Bioinform..

[28]  Naomi Luxford,et al.  Integrated decision-making about housing, energy and wellbeing: a qualitative system dynamics model , 2016, Environmental Health.

[29]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[30]  Helen Y Wang,et al.  Cell type-specific function of TAK1 in innate immune signaling. , 2013, Trends in immunology.

[31]  Y. Fukuoka,et al.  A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs , 2013, Bioinformation.

[32]  Xiang Zhang,et al.  Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..

[33]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[34]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[35]  Mickael Guedj,et al.  Should We Abandon the t-Test in the Analysis of Gene Expression Microarray Data: A Comparison of Variance Modeling Strategies , 2010, PloS one.

[36]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[37]  B Nebiyou Bekele,et al.  Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice , 2006, Clinical Cancer Research.

[38]  Mahitosh Mandal,et al.  Concurrent Cetuximab and Bevacizumab Therapy in a Murine Orthotopic Model of Anaplastic Thyroid Carcinoma , 2007, The Laryngoscope.

[39]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[40]  Michael Hay,et al.  Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.

[41]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..